Advertisement
Advertisement
U.S. Markets close in 4 hrs 25 mins
Advertisement
Advertisement
Advertisement
Advertisement

Spectral Medical Inc. (SD4.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
0.2160+0.0020 (+0.93%)
As of 04:29PM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2140
Open0.2160
Bid0.2160 x 0
Ask0.2420 x 0
Day's Range0.2160 - 0.2160
52 Week Range0.1740 - 0.4200
Volume0
Avg. Volume10
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 22, 2023 - Mar 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Spectral Medical Provides Update on Tigris Clinical Trial and Other Business Developments

    50 Patients Randomized to Date out of the 150 Total Target to be Enrolled Reports Significant Uptick in Screening and Enrollment Activities TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided a business update focusing on Tigris, the Company’s follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial, which

  • Simply Wall St.

    When Can We Expect A Profit From Spectral Medical Inc. (TSE:EDT)?

    We feel now is a pretty good time to analyse Spectral Medical Inc.'s ( TSE:EDT ) business as it appears the company may...

  • GlobeNewswire

    Spectral Medical Announces Strategic Joint Venture With Infomed to Accelerate Commercialization of Dimi and Sami Dialysis Devices

    Spectral to receive a significant equity stake in the joint venture, while eliminating its need to fund future capital requirements for SAMI and DIMITORONTO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical

Advertisement
Advertisement